Genome-wide scans have detected linkage to celiac disease (CD) in several genomic locations, including 19q13.4. Killer immunoglobulin-like receptor (KIR) genes map to the region and encode receptors of natural killer (NK) cells and certain T cells that modulate cytolitic activity through interactions with HLA class I ligands, participating in the innate immune response. We performed KIR genotyping in a group of 70 CD patients of Basque origin and compared gene content, genotype and haplotype frequencies to ethnically matched blood-donors. The frequency of gene combination KIR2DL5B þ /KIR2DL5A À was significantly higher in the disease group, and this result was confirmed in a second group of 343 CD patients and 160 controls of Spanish origin, suggesting an implication of this 'unexpressed' gene with increased susceptibility to CD (combined OR of 3.63 (95% CI: 1.76-7.51; P ¼ 0.0004)), possibly due to the lack of an efficient inhibitory signal. Our results support the role of the KIR gene cluster in celiac disease and replicate the CD-susceptibility locus at 19q13.4.
Introduction
Gluten sensitive enteropathy (MIM 212750) or celiac disease (CD) is a chronic, autoimmune disorder caused by intolerance to ingested gluten that occurs in genetically susceptible individuals. 1 It usually presents as a histologic lesion of the jejunum, consisting of atrophy of the intestinal villi and crypt hyperplasia, with a very wide range of clinical and functional expression. [2] [3] [4] Familial clustering of celiac disease has been known for a long time, with concordance rates between identical twins close to 70%, and around 10% of first-degree relatives of celiac patients affected. 5 A large amount of evidence has identified the major susceptibility locus in the MHC region on chromosome 6p21 and more than 90% of patients with CD express the HLA-DQ2 heterodimer, encoded by DQA1*05 and DQB1*02, in cis position in HLA-DR3 patients, or in trans position in HLA-DR5/DR7 heterozygous patients. The minority of patients lacking HLA-DQ2 presents the HLA-DQ8 molecule, encoded by DQA1*0301 and DQB1*0302. 1 Overall, it is believed that the contribution of the HLA region to CD susceptibility might be close to 40%, but less is known about the remaining genes involved in the predisposition to the disease. 6 Candidate strategies have shown some evidence of the implication of several genes like CTLA4, ICOS, IFNG or MICA, but these findings have not always been replicated in the different populations studied. [7] [8] [9] [10] [11] [12] [13] Genome-wide linkage studies have also been performed, and strong candidate regions for susceptibility loci include 11p11, 5q31 and 19q13.4, [14] [15] [16] but no candidate genes in these regions have been confirmed so far.
The implication of the adaptive immune system through DQ2-restricted gliadin-activated T lymphocytes in the pathogenesis of celiac disease is well documented, 1 but there is growing evidence supporting the role of the innate immune system in the initial stages of CD, that would respond to gliadin in a Tab-lymphocyte independent manner and contribute to the creation of the proinflammatory environment necessary for T-cell activation. [17] [18] [19] Killer Immunoglobulin-like receptors also participate in the innate immune response and are members of the immunoglobulin superfamily that are expressed by natural killer (NK) cells and certain subsets of T cells. KIR molecules are specific for allelic forms of HLA class I antigens and through their interaction produce positive/negative signals that modulate the cytolytic activity of NK cells. To date, 16 different functional KIR genes and two pseudogenes have been described. KIR molecules differ in the number of extracellular Ig-like domains (2 or 3) and in the length of the cytoplasmic tail. The latter distinguishes inhibitory and activating receptors, so inhibitory KIR molecules are characterized by long cytoplasmatic tails (encoded by 'L' KIR genes) while activating KIRs present short cytoplasmatic tails ('S' KIR genes). 20, 21 In humans, KIR genes are associated in several different combinations or haplotypes, formed during human evolution, as a result of extensive gene duplication and unequal crossing over events, facilitated by sequence similarities, gene organization and proximity. 22 The KIR gene cluster presents extraordinary diversity, its variation being a function of both allelic polymorphims at several KIR loci, together with variability in the number (and type) of genes present on a given haplotype. 23, 24 In general, two major groups of haplotypes can be distinguished based on the number and type of KIR genes included. 23 A haplotypes are relatively homogenous and are devoid of activating KIR genes except KIR2DS4 (which however is frequently corrupted leading to a deletion of transmembrane and cytoplasmatic tail). 25 In turn, B haplotypes exhibit substantial variation in gene content and carry more activating KIR genes (up to 6) than group A. 26 A subset of 'framework' genes (KIR3DL2, KIR3DL3 and KIR2DL4) appears in all haplotypes described to date. Several studies have tried to detect association between KIR genes and risk to autoimmune diseases, and for example, the presence of certain activating KIR genes has been associated with rheumatoid arthritis 27, 28 type I diabetes, 29 psoriatic arthritis 30 and psoriasis. 31 The KIR gene cluster is a putative candidate locus for CD susceptibility, both because of the role of KIRs in the innate immune response, and also because KIR genes are located on 19q13.4, a region where linkage to CD has been replicated in genome-wide linkage scans in Irish and UK populations and in fact, the two markers showing the strongest linkage in these two populations (D19S418 and D19S210, respectively) flank the KIR gene cluster. 14, 16 However, a subsequent study in Caucasians from the UK has failed to prove association of KIR genes with CD and confirm the locus on 19q13.4. 32 In the present study, we analyzed the contribution of KIR genes to the genetic predisposition to celiac disease in Basques, an ancient European population that has been isolated in the past and maintains certain genetic characteristics distinctive from other Caucasians, including KIR gene frequencies. [33] [34] [35] [36] We have studied KIR gene content, genotype and haplotype frequencies, as well as combinations with known ligands (HLA-C80) in Basque patients with the disease, and compared them to the general population of the same ethnic origin. An independent sample of Spanish CD patients and non-celiac controls was subsequently analyzed to replicate the association of genotype KIR2DL5B þ /KIR2DL5A À with the disease.
Results and discussion
KIR genotyping of patients of Basque origin with celiac disease and comparison of gene frequencies with the Basque general population did not show any bias in the overall distribution of activating and inhibitory receptors, nor in the frequencies of individual genes (Table 1) . However, there was a significant increase in the proportion of Basque CD patients carrying unexpressed KIR2DL5B*002/004 alleles in the absence of functional KIR2DL5A*001 or KIR2DL5B*003 variants (KIR2DL5B þ / KIR2DL5A À ), compared to ethnically matched healthy blood donors (Table 2 ). This association was confirmed in an independent sample of Spanish CD patients and controls (Table 2 ) and, for the combined sample set, an overall OR of 3.63 (95% CI:1.76-7.51; P ¼ 0.0004) was obtained.
A total of 48 different KIR genotypes were identified in our Basque study population, 21 of which were exclusive of the disease group, although they appeared in only 1.5-4.3% of the patients (Figure 1) . None of the genotypes was significantly increased in the CD group, and although genotypes C and Q showed a tendency suggestive of protection from the disease, statistical significance did not hold after correcting for the number The study population consisted of 70 unrelated individuals of Basque origin with celiac disease, together with geographically and ethnically matched 71 unrelated healthy blood donors whose KIR distribution was described in a previous study of our group. 33 KIR genotyping was performed using a commercial SSP-PCR typing kit (Pel-Freez KIR genotyping SSP kit; Dynal Biotech, Brown Deer, WI, USA) according to the manufacturer's instructions. Genotyping was performed using published PCR primers and methods: 2DL5A*001 typing amplifies expressed variants (2DL5A*001 and 2DL5B*003) and 2DL5B*002 typing amplifies the non-expressed variants (2DL5B*002 and 2DL5B*004). 40 An independent sample of 343 Spanish CD patients and 160 unrelated control individuals was genotyped to replicate the association detected in the Basque sample set. Results were compared using 2 Â 2 contingency tables using Fisher's exact test.
Association of KIR2DL5B with celiac disease I Santin et al of comparisons (n ¼ 48). Using the haplotype subtraction strategy and nomenclature defined by Hsu et al., 25 25 haplotypes were defined in the Basque sample set, five of which (BH4-BH8) appear only in the patient group and have not been described previously (Figure 2 ). Differences in individual haplotype frequencies between patients and controls did not reach statistical significance. However, as a group, haplotypes carrying unexpressed KIR2DL5B but lacking KIR2DL5A (profiles 8, 13, 18 and 19) were increased among Basque CD patients compared to controls (P ¼ 0.03). In those few cases when the risk-conferring haplotypes did appear in the general population, they were always in combination with KIR2DL5A þ haplotypes, resulting in a non-risk genotype. Nevertheless, one must be cautious when interpreting results obtained using haplotype inferring methods, since no biological evidence of the existence of these gene combinations exists.
Our results support the implication of KIR2DL5B in the development of CD, when the closely related KIR2DL5A inhibitory receptor is absent. KIR2DL5B was initially believed to be a non-expressed allelic form of KIR2DL5, but it is now accepted that KIR2DL5A and KIR2DL5B are independent genes that differ in seven nucleotide positions. 38, 39 No transcripts of the major variant of the gene, KIR2DL5B*002, have been detected in PBMC, and several nucleotide substitutions have been identified in the promoter region. 40 Other less frequent variants of this gene have been described in Black and Chinese populations (KIR2DL5B*003 (the only expressed allele), *004, *006 and *007). 38, 41 Although the ligands for the expressed KIR2DL5 receptors have not been identified, 2DS2  2DL2  2DL3  2DL5B  2DS3  2DP1  2DL1  3DP1  3DL1  3DS1  2DL5A  2DS5  2DS1  2DS4  2DS4∆  CD  ( Figure 1 KIR genotypes identified in the present study, some of which have been previously described by Hsu et al., 25 Santin et al. 36 or Jiang et al. 37 Twelve genotypes (BG14-BG25) are previously undescribed haplotype combinations. It was impossible to deduce haplotype combinations for genotypes (UKN1-UKN20). Gene frequencies in the Basque general population were obtained in a previous work of our group. 36 Frequencies were compared using 2 Â 2 contingency tables and P-values were corrected for the number of tests (n ¼ 48).
Association of KIR2DL5B with celiac disease I Santin et al subjects carrying only the silent variants of the gene (KIR2DL5B*002) lack an inhibitory signal and might present a reduced threshold for NK cell activation that could lead to an increased effect of their cytolitic activity. Several authors have proposed that a reduced inhibition of NK cells, due to the absence of inhibitory KIR molecules or of their ligands, might provoke an autoimmune response against different tissues. It has been shown that individuals with activating KIR2DS1 and/or KIR2DS2 present enhanced susceptibility to developing psoriatic arthritis only when the ligands for their homologous inhibitory receptors (KIR2DL1 and KIR2DL2) were absent. 42 Other studies have also supported that a decreasing potential for HLA-C-mediated inhibition may be implicated in the development of autoimmune diseases. 43, 44 In the case of KIR2DL5B þ / KIR2DL5A À -determined susceptibility to CD, it could be speculated that an inhibitory signal does not reach the NK cell because the corresponding receptor is missing, and NK-mediated cell-destruction is not impaired. Interestingly, some evidences support that KIR can bind to non-HLA class I molecules, either expressed by stressed self-cells or encoded by pathogens. 45 A dysregulated NK cell activity could also lead to an uncontrolled response against intestinal bacterial microflora provoking a chronic intestinal inflammation among CD-prone patients. Altogether, the inability to downregulate the activated innate immune environment could constitute a crucial situation for the subsequent action of the T-cell-driven adaptive response that is a hallmark of CD pathogenesis.
Finally, since the effect of KIR genes might depend on the presence or absence of their ligands, we also analyzed several KIR/HLA-C80 combinations that have been previously associated with other autoimmune or inflammatory diseases, including psoriasis, psoriatic arthritis, type I diabetes mellitus and rheumatoid arthritis. 29, 46 When we analyzed activating KIR2DS1 and inhibitory KIR2DL1 in combination with group 2 HLA-C alleles (Lys80), and KIR2DL2/2DL3 and KIR2DS2 in combination with group 1 HLA-C alleles (Asn80), two combinations presented differential distribution among celiac patients and the general population. Inhibitory KIR2DL2/2DL3 in conjunction with group 1 (Asn80) HLA-C alleles was present in the 64% of celiac patients and in the 33% of healthy subjects (P ¼ 0.00015). On the other hand, activating KIR2DS2 in the presence of Asn80 was present in the 38% of celiac patients and in the 20% of healthy subjects (P ¼ 0.013). These differences pointed toward a possible contribution of these allelic combinations to the susceptibility to CD. However, stratified analysis demonstrated that these associations were due to the differential distribution of HLA-C80 variants between the two groups. These results confirm the implication of the HLA region in the disease, but due to the extraordinarily high degree of LD in the MHC region, our study design is not able to determine whether the contribution of HLA-C is indeed independent from HLA class II loci. It could also be possible that the degree of association of the risk KIR2DL5B þ /KIR2DL5A À genotype varied among patients according to the degree of HLA-conferred risk, but no distribution bias was observed when patients were divided according to the number of HLA-DR3 haplotypes. A larger sample size will probably be needed to detect possible genetic interactions between these two loci.
In summary, our results support the implication of KIR genes in the susceptibility to CD, and verify a candidate Frecuency   2DS1  2DS4  2DS4∆  CD  n=132  3DL1  3DS1  2DL5A  2DS5  2DL1   KIR haplotypes  Profile  2DS2  2DL2  2DL3  2DL5B  2DS3 2DP1 3DP1 Figure 2 Twenty-five KIR haplotypes were found in our population. Five haplotypes (BH4-BH8) have not been previously identified, while the rest have been described by Hsu et al. 25 or Santin et al.
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gene for the susceptibility locus located on chromosome 19q13.4. The mechanisms by which the KIR2DL5B þ / KIR2DL5A À gene combination confers susceptibility to the disease remain unclear: the possibility that the expression of KIR2DL5B is restricted to immune cells from the gut must be investigated, and the ligands for KIR2DL5 receptors need to be identified. In this context, it is also possible that KIR2DL5B is a marker of susceptibility to CD that is in strong LD with the risk variant of the etiological gene.
